These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 14529915

  • 1. Effect of immunosuppressive regimen on acute rejection and liver graft function.
    Ziolkowski J, Paczek L, Niewczas M, Senatorski G, Oldakowska-Jedynak U, Wyzgal J, Foroncewicz B, Mucha K, Zegarska J, Nyckowski P, Zieniewicz K, Patkowski W, Krawczyk M, Ziarkiewicz-Wroblewska B, Gornicka B.
    Transplant Proc; 2003 Sep; 35(6):2281-3. PubMed ID: 14529915
    [Abstract] [Full Text] [Related]

  • 2. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R, Yao GL, Meads C, Bayliss S, Ready A, Raftery J, Taylor RS.
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [Abstract] [Full Text] [Related]

  • 3. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation.
    Becker T, Foltys D, Bilbao I, D'Amico D, Colledan M, Bernardos A, Beckebaum S, Isoniemi H, Pirenne J, Jaray J, MARSILEA Study Group.
    Transplantation; 2008 Dec 27; 86(12):1689-94. PubMed ID: 19104406
    [Abstract] [Full Text] [Related]

  • 4. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation.
    Schuller S, Wiederkehr JC, Coelho-Lemos IM, Avilla SG, Schultz C.
    Transplant Proc; 2005 Mar 27; 37(2):1151-2. PubMed ID: 15848653
    [Abstract] [Full Text] [Related]

  • 5. Anti-interleukin 2 receptor antibodies and mycophenolate mofetil for treatment of steroid-resistant rejection in adult liver transplantation.
    Orr DW, Portmann BC, Knisely AS, Stoll S, Rela M, Muiesan P, Bowles MJ, Heaton ND, O'Grady JG, Heneghan MA.
    Transplant Proc; 2005 Dec 27; 37(10):4373-9. PubMed ID: 16387124
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation.
    Ahsan N, Holman MJ, Jarowenko MV, Razzaque MS, Yang HC.
    Am J Transplant; 2002 Jul 27; 2(6):568-73. PubMed ID: 12118902
    [Abstract] [Full Text] [Related]

  • 8. Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study.
    Lin M, Ming A, Zhao M.
    Clin Transplant; 2006 Jul 27; 20(3):325-9. PubMed ID: 16824149
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients.
    Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V, Miller J.
    Transplantation; 2002 Apr 15; 73(7):1100-6. PubMed ID: 11965039
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A, Arnol M, Omahen K, Oblak M, Vidan-Jeras B, Kmetec A, Bren AF.
    Transplantation; 2010 Apr 27; 89(8):1022-7. PubMed ID: 20075788
    [Abstract] [Full Text] [Related]

  • 14. Long-term outcomes in pediatric liver recipients: comparison between cyclosporin A and tacrolimus.
    Cao S, Cox KL, Berquist W, Hayashi M, Concepcion W, Hammes GB, Ojogho OK, So SK, Frerker M, Castillo RO, Monge H, Esquivel CO.
    Pediatr Transplant; 1999 Feb 27; 3(1):22-6. PubMed ID: 10359027
    [Abstract] [Full Text] [Related]

  • 15. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI, Prats D, Marques M, Ridao N, Conesa J, García Mena M, Torrente J, Barrientos A.
    Transplant Proc; 2003 Aug 27; 35(5):1689-90. PubMed ID: 12962759
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

  • 18. Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current status.
    Swiatecka-Urban A.
    Paediatr Drugs; 2003 Feb 27; 5(10):699-716. PubMed ID: 14510627
    [Abstract] [Full Text] [Related]

  • 19. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation.
    Ekberg H, Bernasconi C, Tedesco-Silva H, Vítko S, Hugo C, Demirbas A, Acevedo RR, Grinyó J, Frei U, Vanrenterghem Y, Daloze P, Halloran P.
    Am J Transplant; 2009 Aug 27; 9(8):1876-85. PubMed ID: 19563339
    [Abstract] [Full Text] [Related]

  • 20. Mycophenolate mofetil in pediatric renal transplantation: non-induction vs. induction with basiliximab.
    Ojogho O, Sahney S, Cutler D, Baron PW, Abdelhalim FM, James S, Zuppan C, Franco E, Concepcion W.
    Pediatr Transplant; 2005 Feb 27; 9(1):80-3. PubMed ID: 15667617
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.